Mersana Therapeutics Inc
1 day chart
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company using its antibody drug conjugate (ADC) platforms to develop ADCs to improve the lives of people fighting with cancer. The Company lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase I/II umbrella trial evaluating UpRi in combination with other ovarian cancer therapies. XMT-1592, its second ADC product candidate targeting NaPi2b-expressing tumors, is developed by using its customizable and homogeneous Dolasynthen platform and is in the dose exploration portion of a Phase I clinical trial. Its early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform and targeting an epitope of human epidermal growth factor receptor 2.
Buy US stocks in Australia with $0 brokerage and trade MRSN today!
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.